Details of Patient’s Age, PSA Value, BSI, Hormonal Status, and Treatment at Time of PET Scan
| Patient no. | Age (y) | PSA (ng/mL) | BSI | Hormonal status | Treatment |
|---|---|---|---|---|---|
| 1 | 77 | 231.6 | 10 | Androgen dependent | Antiandrogen therapy |
| 2 | 64 | 87 | 0 | Androgen dependent | Vaccine protocol |
| 3 | 69 | 14.9 | 0.9 | Androgen dependent | Total androgen blockade |
| 4 | 79 | 1,264.7 | 57.8 | Androgen independent | Taxol-based regime |
| 5 | 76 | 60.2 | 6.3 | Androgen independent | Ketoconazole |
| 6 | 69 | 3.4 | 2.0 | Androgen independent | Taxol-based regime |
| 7 | 66 | 48.7 | 1.4 | Androgen independent | Lupron* |
| 8 | 66 | 22.3 | 0 | Androgen dependent | Antiandrogen therapy |
| 9 | 73 | 24 | 4.7 | Androgen dependent | Antiandrogen therapy |
| 10 | 85 | 488 | 69.9 | Androgen independent | Prednisone |
| 11 | 46 | 35 | 0 | Androgen independent | No specific treatment at time of scan |
| 12 | 69 | 191 | 21.1 | Androgen independent | Antiandrogen withdrawal |
↵* Lupron (leuprolide acetate; TAP Pharmaceuticals, Lake Forest, IL).